The growing prevalence of lysosomal storage diseases around the globe is driving the growth of the lysosomal storage diseases therapeutics market. For instance, according to a report updated by National Center for Biotechnology Information, in January 2020, the prevalence of Fabry disease in white, male populations was 1:17,000 to 1:117,000. Moreover, classic Fabry disease mutations were evident in around 1:22,000 to 1:40,000 males and atypical presentations were associated with about 1:1000 to 1:3000 males and 1:6000 to 1:40,000 females. Growing awareness regarding the rare disease among the population is another key factor augmenting the growth of the lysosomal storage diseases therapeutics market. For instance, the European Organization for Rare Diseases celebrates Rare Disease Day annually on the last day of the month of February.
In January 2020, Quest Diagnostics acquired Blueprint Genetics to expand its product portfolio in genetic and rare diseases
In 2019, Amicus Therapeutics, Inc. collaborated with the University of Pennsylvania, under which the company received disease-specific worldwide rights to the university’s Next Generation Gene Therapy Technologies from the Wilson Lab for LSDs and other twelve rare diseases.
Read More: https://coherentmarketorientedblogs.blogspot.com/2021/07/quest-diagnostics-acquired-blueprint.html
